Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Compliance and regulatory

UNEP and WHO publish first global update on endocrine-disrupting chemicals since 2012

UNEP and WHO’s 17 November 2026 update on endocrine-disrupting chemicals flags a large testing gap across more than 350,000 registered chemicals.

Published 18 Nov 2026· 7 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

The United Nations Environment Programme (UNEP) and the World Health Organization (WHO) published State of the Science of Endocrine-Disrupting Chemicals 2026 on 17 November 2026, the first major global update since their 2012 assessment. It concludes that exposure to hormone-disrupting chemicals can begin before birth and that only a small fraction of the more than 350,000 chemicals and mixtures registered for use has been evaluated for endocrine-disrupting properties, a testing gap that bears directly on toxicology labs, research offices and chemical regulators.

What happened

WHO’s publication record lists the report as edited by UNEP and WHO, 240 pages, released on 17 November 2026. It responds to a request from the United Nations Environment Assembly to update the 2012 State of the Science assessment, and it reviews the most significant scientific advances made since then, according to WHO’s description. A companion synthesis, From Evidence to Action: Addressing Endocrine Disrupting Chemicals Across Sectors, sets out suggested practical actions for policymakers. Both were launched in Geneva at the first International Conference of the Global Framework on Chemicals, which runs from 16 to 20 November 2026.

WHO says stronger evidence now links endocrine-disrupting chemicals (EDCs) to effects on fertility and reproductive development, brain development and neurological function, thyroid and hormone regulation, metabolism, immunity and cardiovascular health. Metabolic liver disease and possible kidney effects are named as newer concerns where important gaps remain. In wildlife, exposure across fish, birds, amphibians and mammals is linked to impaired reproduction, development and behaviour. EDCs have been detected in blood, breast milk and cord blood. Sheila Aggarwal Khan of UNEP said the effects “can be long-lasting and, in some cases, irreversible.”

Key details

Item What the sources report
Report State of the Science of Endocrine-Disrupting Chemicals 2026; 240 pages (WHO publication record)
Release date 17 November 2026
Previous assessments 2002 and 2012 (AP)
Chemicals registered for use More than 350,000 chemicals and mixtures; only a small fraction evaluated for endocrine-disrupting properties (WHO)
Health-related costs Above $1.1 trillion a year worldwide, described by AP as a conservative estimate covering treatment and lost productivity; UN News reports costs could reach one per cent or more of global GDP
Companion document From Evidence to Action: Addressing Endocrine Disrupting Chemicals Across Sectors
Launch venue First International Conference of the Global Framework on Chemicals, Geneva, 16 to 20 November 2026

The testing and assessment gap

WHO states that people and wildlife are exposed to mixtures, yet many regulatory systems still assess chemicals one at a time. AP reports that testing programmes have expanded but that most have not led to regulation or controls on exposure. Laura Vandenberg, the report’s lead author and a professor of environmental health sciences at the University of Massachusetts Amherst, described a “whack-a-mole problem”: when a chemical such as bisphenol A is removed, a structurally similar or inadequately tested substitute often takes its place. The report itself says action is possible without resolving every uncertainty, and that reducing legacy contamination has reversed adverse effects in some cases.

Recommendations

WHO summarises the recommended direction as stronger regulation to phase out the most problematic chemicals and promote safer alternatives, earlier identification of risks, stronger scientific monitoring and coordinated action across sectors, with particular attention to pregnancy, infancy and childhood. AP lists five action areas: protecting vulnerable groups, improving exposure monitoring and understanding, advancing chemical identification and testing, accounting for the costs of exposure, and strengthening regulations. WHO says the companion synthesis covers food packaging, cosmetics, toys, textiles, healthcare, agriculture, pharmaceuticals and waste, and that companies are urged to test early, disclose product ingredients and substitute chemicals proactively.

Background and context

The 2012 UNEP-WHO assessment was the last global stocktake of the science; AP notes that earlier assessments date from 2002 and 2012 and that Vandenberg contributed to the 2012 report. The new edition notes progress in the range of documented health effects, exposure science, testing and assessment methods, and understanding of the socioeconomic costs of regulatory inaction, according to WHO. AP reports that the exposure routes covered include ingestion, skin absorption, inhalation and contact with medical devices, and that EDCs are found in plastics, personal care products, pharmaceuticals, toys, household goods, electronics and pesticides.

The regulatory backdrop differs by region. AP reports that the American Chemistry Council, represented by Kimberly Wise White, argued that comprehensive frameworks such as the US Toxic Substances Control Act and the EU’s REACH regulation are the most effective way to regulate plastic additives. Some countries are pushing to regulate chemicals in plastics within the global plastic pollution treaty talks, which AP says resume early next year; the plastics industry opposes new treaty restrictions and says existing conventions and national laws are better suited.

Reaction

Vandenberg told AP the science now offers “essentially a statement of irrefutable evidence linking EDCs to human health effects and also environmental damage,” adding that “in many, many cases we know enough to act.” Bethanie Carney Almroth, the UN Special Rapporteur on toxics and human rights, said responses need to move from reactive to proactive. Bjorn Beeler of the International Pollutants Elimination Network (IPEN) said the report strengthens countries pushing for controls.

The Health and Environment Alliance (HEAL), in a statement dated 17 November 2026, said the report confirms strengthened evidence of associations between EDC exposure and adverse health outcomes and recognises the EU’s role in identifying EDCs. Executive Director Genon K. Jensen called for “decisive action from the European Commission on restricting EDCs”. HEAL urged restrictions on groups of problematic EDCs through the REACH restrictions roadmap, new REACH authorisations and new sectoral requirements, for example for cosmetic products, in line with the EU Chemicals Strategy for Sustainability.

What it means for researchers, universities and research offices

The report’s own framing points to several concrete areas for the research community. Toxicology and environmental-health groups work in the territory the report calls underassessed: with only a small fraction of registered chemicals evaluated for endocrine activity, and substitutes often inadequately tested, studies that screen replacement compounds and mixtures address the gap the authors describe. Methods work is explicitly in scope, since the report notes progress in testing and assessment methods and lists advancing chemical identification and testing among its action areas. Background on the field is in the CASRAI guides on toxicology and the dictionary entry on new approach methodologies.

Exposure monitoring is a second area. WHO’s call for stronger scientific monitoring and AP’s description of improved exposure monitoring and understanding imply continued demand for biomonitoring and exposure-assessment studies, and the evidence-synthesis work that interprets them, such as risk-of-bias assessment for studies of exposures. The documented costs of exposure, which the report says are not fully captured in current estimates, point to health-economics work as a further need.

For research offices and laboratories that handle and register chemicals, the regulatory frameworks named in the coverage, TSCA in the United States and REACH in the EU, are the instruments the industry and campaigners both cite. CASRAI explains how REACH applies to a chemical-handling research lab and what the TSCA research and development exemption covers and does not cover. Any change to how endocrine disruptors are identified or restricted would reach laboratories through those channels, not through the report itself, which offers options for decision-makers rather than binding rules.

What happens next

The Global Framework on Chemicals conference continues in Geneva until 20 November 2026, where the report and its companion synthesis were launched. AP reports that negotiations on the global plastic pollution treaty resume early next year, where chemicals in plastics are among the contested issues. HEAL’s calls for EU action are directed at the European Commission. The sources set out calls for action rather than a dated restriction.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →